Literature DB >> 9176711

A sensitive and robust assay for urokinase and tissue-type plasminogen activators (uPA and tPA) and their inhibitor type I (PAI-1) in breast tumor cytosols.

N Grebenschikov1, A Geurts-Moespot, H De Witte, J Heuvel, R Leake, F Sweep, T Benraad.   

Abstract

uPA and PAI-1 are becoming established as amongst the most effective markers of poor prognosis for patients with node-negative breast cancer; tPA is an index of longer survival. This paper describes a sensitive ELISA for the measurement of uPA, tPA and PAI-1 in breast cancer cytosols. The structure of the assay involves coating Ab (sheep alpha-Chicken IgY), catching Ab (chicken alpha-analyte), tagging Ab (rabbit alpha-analyte) and detecting Ab (goat alpha-rabbit IgG) labelled with HRP. The assay has a high degree of accuracy and specificity. Comparison with the American Diagnostic kits shows the results' equivalence for PAI-1 and tPA. For uPA the results of the assay were twice as high. The assay is sensitive and relatively inexpensive. It is the first published assay to yield strictly comparative values for uPA, tPA and PAI-1 in tissue extracts and is readily subject to external quality control.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9176711     DOI： 10.1177/172460089701200102

Source DB:  PubMed          Journal:  Int J Biol Markers        ISSN： 0393-6155            Impact factor:   3.248


  9 in total

1.  High production of proinflammatory and Th1 cytokines by dendritic cells from patients with rheumatoid arthritis, and down regulation upon FcgammaR triggering.

Authors:  T R D J Radstake; P L E M van Lent; G J Pesman; A B Blom; F G J Sweep; J Rönnelid; G J Adema; P Barrera; W B van den Berg
Journal:  Ann Rheum Dis       Date:  2004-06       Impact factor: 19.103

2.  Adult patients with congenital adrenal hyperplasia have elevated blood pressure but otherwise a normal cardiovascular risk profile.

Authors:  Christiaan F Mooij; Jeanne Margot Kroese; Fred C G J Sweep; Ad R M M Hermus; Cees J Tack
Journal:  PLoS One       Date:  2011-09-01       Impact factor: 3.240

3.  Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer.

Authors:  A Knoop; P A Andreasen; J A Andersen; S Hansen; A V Laenkholm; A C Simonsen; J Andersen; J Overgaard; C Rose
Journal:  Br J Cancer       Date:  1998-03       Impact factor: 7.640

4.  Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer.

Authors:  J H de Witte; C G Sweep; J G Klijn; N Grebenschikov; H A Peters; M P Look; T H van Tienoven; J J Heuvel; J Bolt-De Vries; T J Benraad; J A Foekens
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

5.  High tPA-expression in primary melanoma of the limb correlates with good prognosis.

Authors:  C M Ferrier; S Suciu; W L van Geloof; H Straatman; A M Eggermont; H S Koops; B B Kroon; F J Lejeune; U R Kleeberg; G N van Muijen; D J Ruiter
Journal:  Br J Cancer       Date:  2000-11       Impact factor: 7.640

6.  Comparison of immunohistochemistry with immunoassay (ELISA) for the detection of components of the plasminogen activation system in human tumour tissue.

Authors:  C M Ferrier; H H de Witte; H Straatman; D H van Tienoven; W L van Geloof; F J Rietveld; C G Sweep; D J Ruiter; G N van Muijen
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

7.  Induction of plasminogen activator inhibitor type-1 (PAI-1) by hypoxia and irradiation in human head and neck carcinoma cell lines.

Authors:  Daniela Schilling; Christine Bayer; Anneke Geurts-Moespot; Fred C G J Sweep; Martin Pruschy; Karin Mengele; Lisa D Sprague; Michael Molls
Journal:  BMC Cancer       Date:  2007-07-30       Impact factor: 4.430

8.  External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts.

Authors:  C G Sweep; J Geurts-Moespot; N Grebenschikov; J H de Witte; J J Heuvel; M Schmitt; M J Duffy; F Jänicke; M D Kramer; J A Foekens; N Brünner; G Brugal; A N Pedersen; T J Benraad
Journal:  Br J Cancer       Date:  1998-12       Impact factor: 7.640

9.  Protein kinase Cdelta expression in breast cancer as measured by real-time PCR, western blotting and ELISA.

Authors:  E McKiernan; K O'Brien; N Grebenchtchikov; A Geurts-Moespot; A M Sieuwerts; J W M Martens; V Magdolen; D Evoy; E McDermott; J Crown; F C G J Sweep; M J Duffy
Journal:  Br J Cancer       Date:  2008-10-28       Impact factor: 7.640
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.